Aytu Biopharma, Inc.
AYTU Nasdaq
SEC CIK 1385818
Follow Aytu Biopharma
Weekly email: filings, results
Revenue, last quarter
$14.8M
+6.9% vs same quarter last year
Net income
−$3.9M
EPS, diluted
−$0.20
−195.2% vs same quarter last year
Operating cash flow
−$275K
+55.5% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY26 | $57.6M | −$14.3M |
| FY25 | $66.4M | −$13.6M |
| FY24 | $65.2M | −$15.8M |
| FY23 | $107.4M | −$17.1M |
| FY22 | $96.7M | −$108.8M |
| FY21 | $65.6M | −$58.3M |
| FY20 | $27.6M | −$13.6M |
| FY19 | $7.3M | −$27.1M |
| FY18 | $3.7M | −$10.2M |
| FY17 | $3.2M | −$22.5M |
| FY16 | $2.6M | −$28.2M |
| FY15 | $261.8K | −$7.7M |
| FY14 | $58.9K | −$5.6M |
| FY13 | - | −$59.7K |
| FY12 | - | −$136.8K |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY26 | 64% | −14.4% | −24.8% |
| FY25 | 69% | −11.8% | −20.5% |
| FY24 | 75.3% | −2.4% | −24.2% |
| FY23 | 62% | −15.9% | −15.9% |
| FY22 | 54.1% | −113.7% | −112.5% |
| FY21 | 44.5% | −89.7% | −88.8% |
| FY20 | 70% | −76.5% | −49.3% |
| FY19 | 69.9% | −230.1% | −370.6% |
| FY18 | 44% | −538.2% | −278.3% |
| FY17 | 56% | −624.7% | −698.7% |
| FY16 | 62.6% | −847% | −1099.7% |
| FY15 | 66.3% | −2915.5% | −2950.3% |
| FY14 | - | −10770.3% | −9466.8% |
| FY13 | - | - | - |
| FY12 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY26 | $3.3M |
| FY25 | −$2.2M |
| FY24 | −$1.7M |
| FY23 | - |
| FY22 | −$28.8M |
| FY21 | −$28.3M |
| FY20 | −$28.4M |
| FY19 | −$13.9M |
| FY18 | −$16M |
| FY17 | −$13.9M |
| FY16 | −$10.9M |
| FY15 | −$6.6M |
| FY14 | −$47K |
| FY13 | - |
| FY12 | - |
- Aytu Biopharma
- Healthcare median
Show the numbers
| Year | Aytu Biopharma | Healthcare median |
|---|---|---|
| FY26 | −24.8% | −11.1% |
| FY25 | −20.5% | −30.6% |
| FY24 | −24.2% | −47% |
| FY23 | −15.9% | −58% |
| FY22 | −112.5% | −80.4% |
| FY21 | −88.8% | −71.9% |
| FY20 | −49.3% | −62.2% |
| FY19 | −370.6% | −46.3% |
| FY18 | −278.3% | −49.6% |
| FY17 | −698.7% | −45.9% |
| FY16 | −1099.7% | −36% |
| FY15 | −2950.3% | −38.4% |
| FY14 | −9466.8% | −35.5% |
| FY13 | - | −37.1% |
| FY12 | - | −29.1% |